Abilita Bio, Inc., a biotechnology company based in San Diego, California, recently raised $7.5 million in funding from Two Bear Capital. The startup was founded in June 2014 and is focused on enabling the discovery and development of drugs that target membrane proteins, including G protein-coupled receptors (GPCRs) and ion channels. Membrane proteins are the targets of over half of all drugs currently on the market and are crucial for a wide range of biological processes in the body.

Abilita Bio has established collaborations with pharmaceutical and biotechnology companies around the world and seeks to expand these collaborative research agreements to accelerate the development of new treatments for a variety of diseases.

The company's platform technology enables high-throughput screening of drug candidates against membrane proteins, allowing for the rapid identification of promising drug candidates.

The company is currently incubating at JLabs San Diego, a life science innovation center operated by Janssen Research & Development. JLabs provides Abilita Bio with access to state-of-the-art facilities, expertise, and resources that can help the company accelerate the development of its drug discovery platform and bring new treatments to patients faster.

With the new funding, Abilita Bio is well-positioned to continue its work on membrane protein drug discovery and development. The company plans to use the investment to further develop its platform technology, expand its collaborations with pharmaceutical and biotechnology companies, and explore new market opportunities.

Abilita Bio's innovative approach to drug discovery and development, combined with its world-class team of scientists and collaborators, makes it a promising player in the biotechnology industry.

Abilita Bio's recent funding round is a significant milestone for the company and highlights the growing importance of membrane protein drug targets in the biotechnology industry.

With continued investment and collaboration, Abilita Bio is well-positioned to make important contributions to the development of new and effective treatments for a wide range of diseases. For more information about Abilita Bio, visit our founder lodge funding round.